Predictive Value of Soluble Growth Stimulator Gene 2 Protein for Coronary Slow Flow/No-Reflow in ST-Elevation Myocardial Infarction Patients Receiving Percutaneous Coronary Intervention

Table1

Baseline characteristics of study population, mean ± SD or n (%).

Variable	Control group (n = 192)	CSF/NRF(n = 50)
Age (years)	61.2 ± 12.2	66.6 ± 12.0	0.006
Male (n, %)	144 (75.0)	36 (72.0)	0.655
Hypertension (n, %)	100 (52.1)	20 (40)	0.128
Diabetes mellitus (n, %)	47 (24.5)	21 (42.0)	0.014
Smoking (n, %)	115 (60.0)	26 (52.0)	0.313
BMI (kg/㎡)	24.5 (22.4, 26.8)	24.7 (20.7, 27.8)	0.774
Preinfarction angina (n, %)	31 (16.1)	10 (20.0)	0.518
Killip grade (n, %)	—	—	0.578
Killip I	163 (84.7)	44 (88.4)	—
Killip ≥ II	29 (15.3)	6 (11.6)	—
Time to reperfusion (min)	344.0 (196.0, 545.8)	305.5 (208.8, 609.3)	0.967
sST2 (ng/ml)	46.5 (35.6, 64.0)	80.6 (55.1, 121.4)	≤0.001
Peak NT-proBNP (ng/L)	1595.0 (709.5, 2942.3)	1831.0 (1040.0, 3650.0)	0.048
Peak CK-MB (U/L)	66.0 (33.1, 135.8)	121.0 (73.1, 187.8)	≤0.001
Peak cTNI (pg/ml)	2.7 (1.3, 7.1)	5.3 (3.5, 8.0)	≤0.001
NRL	3.9 (2.5, 6.6)	6.3 (3.4, 10.9)	≤0.001
WBC (10^9)	9.91 ± 3.41	9.93 ± 3.60	0.974
Fibrinogen (g/L)	2.7 (2.2, 3.2)	2.6 (2.1, 3.1)	0.614
LDL-C (mmol/L)	3.1 ± 0.9	2.8 ± 0.7	0.061
Blood uric acid (ummol/L)	353.5 (278.5, 419.8)	354.5 (274.5.0, 412.0)	0.735
Fasting blood sugar (mmol/L)	6.2 (5.0, 7.9)	6.9 (6.0,9.3)	0.008
Lipoprotein α (mg/dl)	145.5 (86.3, 256.6)	206.7 (88.4, 285.5)	0.273
CCr (ml/min)	94.8 (69.5, 121.1)	81.5 (67.4, 106.8)	0.090
LVEDV (mm)	99.5 (86.8, 107.3)	100.0 (90.0, 120.0)	0.313
LVESV (mm)	52.0 (41.3, 62.8)	52.0 (43.0, 59.3)	0.609
EF (%)	0.42 (0.38, 0.46)	0.41 (0.38, 0.44)	0.104

Bold values are statistically significant ().